Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMINENT pemafibrate cardiovascular outcomes trial in type 2 diabetes with atherogenic dyslipidemia
NL-OMON53131Phase 3Active, not recruiting
- Sponsor
- Kowa Research Institute, Inc.
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertriglyceridemia, dyslipidemia, type 2 diabetes mellitus (T2DM) and 1 more comparing Pemafibrate with Placebo (2 arms). Primary endpoint: Primary efficacy composite endpoint. Started Aug 2017; status: active, not recruiting.
02
Drugs
pemafibrate
03
Conditions
hypertriglyceridemiadyslipidemiatype 2 diabetes mellitus (T2DM)cardiac morbidity
Beyond the preview
Go deeper on NL-OMON53131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53131.